4 ms·
Doesn't it incentivize development of "mostly safe" vaccines, over "completely safe but more expensive". As long as the number of litigants remains low, it cou
by Andys 6y ago
Doesn't it incentivize development of "mostly safe" vaccines, over "completely safe but more expensive". As long as the number of litigants remains low, it could be more cost effective to pay them off.
- steverb 6y agoI would think so, yes, although I doubt that "completely safe" is an achievable reality.